The estimated Net Worth of Thomas C Lavoy is at least $121 millier dollars as of 1 March 2018. Thomas Lavoy owns over 50,000 units of Perspective Therapeutics Inc stock worth over $121,472 and over the last 17 years Thomas sold ISR stock worth over $0.
Sign up
Thomas Lavoy ISR stock SEC Form 4 insiders trading
Thomas has made over 9 trades of the Perspective Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas bought 50,000 units of ISR stock worth $22,000 on 1 March 2018.
The largest trade Thomas's ever made was exercising 82,810 units of Perspective Therapeutics Inc stock on 20 November 2017 worth over $50,514. On average, Thomas trades about 18,394 units every 163 days since 2007. As of 1 March 2018 Thomas still owns at least 316,333 units of Perspective Therapeutics Inc stock.
You can see the complete history of Thomas Lavoy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Thomas Lavoy's mailing address?
Thomas's mailing address filed with the SEC is C/O SUPERSHUTTLE INTERNATIONAL INC, 14500 N. NORTHSIGHT BLVD., SUITE 329, SCOTTSDALE, AZ, 85260.
Insiders trading at Perspective Therapeutics Inc
Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy et Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.
What does Perspective Therapeutics Inc do?
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
What does Perspective Therapeutics Inc's logo look like?
Complete history of Thomas Lavoy stock trades at Perspective Therapeutics Inc
Perspective Therapeutics Inc executives and stock owners
Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lori Woods,
Chief Executive Officer, Director -
Lori A. Holmes-Woods,
CEO & Director -
Michael Krachon,
Executive Vice President of Sales and Marketing -
William Cavanagh,
Chief Research and Development Officer -
Michael L. Krachon,
Exec. VP of Sales & Marketing -
Jennifer Streeter,
COO & VP of HR -
William A. Cavanagh III,
Chief R&D Officer -
Krista Cline,
Senior Director of Operations, Corporate Secretary -
Philip Vitale,
Independent Director -
Alan Hoffmann,
Independent Director -
Jonathan Hunt,
Chief Financial Officer, Co-Principal Financial Officer -
Mark Austin,
Controller, Co-Principal Financial and Principal Accounting Officer -
Jennifer Streeter,
Chief Operating Officer, Vice President of Human Resources -
Michael McCormick,
Independent Chairman of the Board -
Krista Cline,
Sr. Director of Operations & Corp. Sec. -
Mark J. Austin CPA,
VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. -
Jonathan R. Hunt,
CFO & Co-Principal Financial Officer -
Frank Morich,
Director -
Brien Ragle,
Controller -
Dwight William Babcock,
CEO -
Matthew Branson,
Principal Fin & Acct Officer -
Robert F Iii Williamson,
Director -
Thomas C Lavoy,
Director -
Albert Louis Smith,
Director -
Roger Girard,
CEO/President -
Robert R Kauffman,
Director -
Fredric Swindler,
Vice President -
David Swanberg,
EVP Operations & Secretary -
Stephen Boatwright,
Director